BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests

Reuters

Jun 12, 2025

BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests

** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise 17.5% to $70 premarket

** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test

** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests

** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active

** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches

** Semaglutide, sold by Danish drugmaker Novo Nordisk NOVOb.CO, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity

** As of last close, IPA's stock was up 45.8% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2542511590"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542511590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542511590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542511590","market":"nz","top_or_hot":-1,"title":"BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests</title></head><body><p>** Shares of biotech firm ImmunoPrecise Antibodies <span>IPA.O</span> rise 17.5% to $70 premarket</p><p>** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test</p><p>** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests</p><p>** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active</p><p>** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches</p><p>** Semaglutide, sold by Danish drugmaker Novo Nordisk <span>NOVOb.CO</span>, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity</p><p>** As of last close, IPA's stock was up 45.8% YTD</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests</title></head><body><p>** Shares of biotech firm ImmunoPrecise Antibodies <span>IPA.O</span> rise 17.5% to $70 premarket</p><p>** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test</p><p>** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests</p><p>** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active</p><p>** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches</p><p>** Semaglutide, sold by Danish drugmaker Novo Nordisk <span>NOVOb.CO</span>, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity</p><p>** As of last close, IPA's stock was up 45.8% YTD</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nL4N3SF0TP:1","article_id":"2542511590","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542511590","pubTimestamp":1749731271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise 17.5% to $70 premarket** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches** Semaglutide, sold by Danish drugmaker Novo Nordisk NOVOb.CO, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity** As of last close, IPA's stock was up 45.8% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"BUZZ-人工智能肽在实验室测试中击败索马鲁肽后，ImmunoPrecise跃升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"BUZZ-ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise 17.5% to $70 premarket** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches** Semaglutide, sold by Danish drugmaker Novo Nordisk NOVOb.CO, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity** As of last close, IPA's stock was up 45.8% YTD(Reporting by Kamal Choudhury in Bengaluru)((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}